DOSAGE INDEX / SINGLE
Oxytocin
Research, reported schedules and supply planning.
Examine oxytocin medical uses, intranasal autism trials, trust research, placebo responses and safety limits with primary-source evidence.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This source-reported experimental schedule is not an obstetric prescription. Do not substitute it for an approved product, indication or monitored clinical protocol.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Sikich and colleagues enrolled 290 autistic children and adolescents aged 3 to 17. The trial compared intranasal oxytocin with placebo over 24 weeks. Its modified intention-to-treat analysis included 277 participants. On the primary ABC modified Social Withdrawal measure, the adjusted between-group difference was -0.2 points, with a 95% confidence interval from -1.5 to 1.0 and P = 0.61. Secondary outcomes generally did not differ. [2]
- The adult multicenter trial reported by Yamasue and colleagues enrolled 106 participants aged 18 to 48 and analyzed 103. After six weeks, social-reciprocity scores improved in both the oxytocin and placebo groups. The primary between-group comparison was not significant, with P = 0.69. Plasma oxytocin increased in the active-treatment group despite the lack of a demonstrated primary clinical advantage. [3]
- The Pitocin injection label describes serious risks including excessive uterine activity, arrhythmias and water intoxication. It specifies hospital medical supervision for induction or augmentation of labor. These warnings concern labeled injection use; they are not numerical estimates of risk from experimental intranasal administration. [1]
- The Sikich trial reported similar adverse-event incidence and severity between its groups. That observation belongs to the monitored trial and its participants. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 34 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- DailyMed product label
- Sikich 2021
- Yamasue 2020
- Parker 2017
- Kosfeld 2005
- Declerck 2020
- Boulton 2026
- Cleveland ClinicFurther reading · Listed in reference bibliography.
- WikipediaFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- Aging JournalFurther reading · Listed in reference bibliography.
- PLOS OneFurther reading · Listed in reference bibliography.
- Science DirectFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- FDA AccessdataRegulatory / product information · Listed in reference bibliography.
- Oxytocin Injection, USP Official Label - Ready sterile 10 USP units/mL IV or IM product with exact labor and postpartum instructions.Regulatory / product information · Listed in reference bibliography.
- Single Subcutaneous Oxytocin Heat-Pain Experiment, PMID 38642595 - Primary crossover study in 18 healthy adults using one 4 microgram dose in 2 mL.Further reading · Listed in reference bibliography.
- Intranasal Oxytocin Pharmacokinetic and CSF Study, PMID 24310737 - Primary study using one 24 IU intranasal administration in healthy participants.Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.